HighVista Strategies’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History
Bought
Maintained
Sold
Other funds holding BMY.RT
JCI
BC
TNB
WAM
IAIM
HighVista Strategies's BMY.RT Position: Q1 2021 in Review
HighVista Strategies sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 180,400 shares — an estimated $124K sold.
HighVista Strategies first reported a position in BMY.RT in Q4 2020 and held it in 1 quarter. The position peaked at $124K in Q4 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.
- HighVista Strategies reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
- HighVista Strategies sold 180,400 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $124K.
- HighVista Strategies first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2020 and held it in 1 quarter.
- HighVista Strategies's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $124K in Q4 2020.
- 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.
Based on HighVista Strategies's 13F filing for Q1 2021, filed 17 May 2021.